ALNY

Alnylam Pharmaceuticals, Inc.

Sağlık

COMPLIANT — All screening ratios are below the thresholds; the company is compliant with halal investment criteria.

$156.65

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %2.8 / %30

Non-compliant assets / Total market cap %5.8 / %30

Non-compliant revenue / Total income %2.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.

Website

Analysis (Turkish): ALNY Hissesi Caiz mi, Helal mi? Alnylam Pharmaceuticals, Inc. Katılım Analizi